Suicidality and divalproex sodium: Analysis of controlled studies in multiple indications

Annals of General Psychiatry

Volumn 10, Issue , 2011, Pages

  Redden, Laura ^a   Pritchett, Yili ^a   Robieson, Weining ^a   Kovacs, Xenia ^a   Garofalo, Mary ^a   Tracy, Katherine ^a   Saltarelli, Mario ^a  

^a ABBOTT LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; PLACEBO; VALPROATE SEMISODIUM;

ADJUVANT THERAPY; ADOLESCENT; ADULT; AGED; AGGRESSION; ARTICLE; BIPOLAR DEPRESSION; BIPOLAR DISORDER; CHILD; COMPLEX PARTIAL SEIZURE; DATA ANALYSIS; DEMENTIA; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG MEGADOSE; EPILEPSY; FEMALE; HUMAN; IMPULSIVENESS; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MANIA; MENTAL DISEASE; META ANALYSIS; METHODOLOGY; MIGRAINE; NARRATIVE; PRESCHOOL CHILD; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; STATISTICAL ANALYSIS; SUICIDAL BEHAVIOR; SUICIDAL IDEATION; SUICIDE; SUICIDE ATTEMPT;

EID: 78651447826     PISSN: None     EISSN: 1744859X     Source Type: Journal    
DOI: 10.1186/1744-859X-10-1     Document Type: Article

References (42)

1. World Health Organization The Global Burden of Disease: 2004 Update. World Health Organization., http://www.who.int/healthinfo/global_burden_disease/2004_report_update/en/index.html
2. Karch DL, Dahlberg LL, Patel N, Davis TW, Logan JE, Hill HA, Ortega L. Surveillance for Violent Deaths-National Violent Death Reporting System, 16 States, 2006. Mortal Morbid Rep 2009, 58:1-48.
3. Posner K, Oquendo MA, Gould M, Stanley B, Davies M. Columbia Classification Algorithm of Suicide Assessment (C-CASA): classification of suicidal events in the FDA's pediatric suicidal risk analysis of antidepressants. Am J Psychiatry 2007, 164:1035-1043. 10.1176/appi.ajp.164.7.1035, 17606655.
4. US Food and Drug Administration Statistical Review and Evaluation, Antiepileptic Drugs and Suicidality. US Food and Drug Administration., http://www.fda.gov/ohrms/dockets/ac/08/briefing/2008-4372b1-01-FDA.pdf
5. US Food and Drug Administration FDA Requires Warnings about Risk of Suicidal Thoughts and Behavior for Antiepileptic Medications. US Food and Drug Administration., http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm100197.htm
6. Layne Moore J, Elliott JO, Lu B, Klatte ET, Charyton C. Serious psychological distress among persons with epilepsy based on the 2005 California Health Interview Survey. Epilepsia 2009, 50:1077-1084. 10.1111/j.1528-1167.2008.01996.x, 19260944.
7. O'Dell C, Wheless JW, Cloyd J. The personal and financial impact of repetitive or prolonged seizures on the patient and family. J Child Neurol 2007, 22:61S-70S.
8. Suurmeijer TP, Reuvekamp MF, Aldenkamp BP. Social functioning, psychological functioning, and quality of life in epilepsy. Epilepsia 2001, 42:1160-1168. 10.1046/j.1528-1157.2001.37000.x, 11580765.
9. Westphal-Guitti AC, Alonso NB, Migliorini RC, da Silva TI, Azevedo AM, Caboclo LO, Sakamoto AC, Yacubian EM. Quality of life and burden in caregivers of patients with epilepsy. J Neurosci Nurs 2007, 39:354-360. 10.1097/01376517-200712000-00006, 18186420.
10. Harris EC, Barraclough B. Suicide as an outcome for mental disorders. A meta-analysis. Br J Psychiatry 1997, 170:205-228. 10.1192/bjp.170.3.205, 9229027.
11. Tellez-Zenteno JF, Patten SB, Jette N, Williams J, Wiebe S. Psychiatric comorbidity in epilepsy: a population-based analysis. Epilepsia 2007, 48:2336-2344.
12. Pompili M, Innamorati M, Del Casale A, Serafini G, Forte A, Lester D, Raja M, Amore M, Tatarelli R, Girardi P. No cathartic effect in suicide attempters admitted to the emergency department. J Psychiatr Pract 2009, 15:433-441. 10.1097/01.pra.0000364284.78457.ea, 19934717.
13. Abbott Laboratories Depakote ER (divalproex sodium extended-release tablets) prescribing information. 2010, Chicago, IL: Abbott, Abbott Laboratories.
14. Gibbons RD, Hur K, Brown CH, Mann JJ. Relationship between antiepileptic drugs and suicide attempts in patients with bipolar disorder. Arch Gen Psychiatry 2009, 66:1354-1360. 10.1001/archgenpsychiatry.2009.159, 19996040.
15. Hesdorffer DC, Kanner AM. The FDA alert on suicidality and antiepileptic drugs: Fire or false alarm?. Epilepsia 2009, 50:978-86. 10.1111/j.1528-1167.2009.02012.x, 19496806.
16. Janati A, Shneker BF, Cios JS, Elliott JO. Suicidality, depression screening, and antiepileptic drugs: reaction to the FDA alert. Neurology 2009, 73:1710. 10.1212/WNL.0b013e3181bd6bd4, 19917998.
17. Shneker BF, Cios JS, Elliott JO. Suicidality, depression screening, and antiepileptic drugs: reaction to the FDA alert. Neurology 2009, 72:987-991. 10.1212/01.wnl.0000344403.13815.8d, 19289738.
18. Cytel Software Corporation StatXact 7 PROCs for SAS Users 2005, Chapter 19. Cambridge, MA: Cytel, Cytel Software Corporation.
19. Schabenberger O. Growing up fast: SAS 9.2 enhancements to the GLIMMIX procedure. SAS Global Forum 2007, Orlando, FL: SAS.
20. Greenland S, Robins JM. Estimation of a common effect parameter from sparse follow-up data. Biometrics 1985, 41:55-68. 10.2307/2530643, 4005387.
21. Busch KA, Fawcett J, Jacobs DG. Clinical correlates of inpatient suicide. J Clin Psychiatry 2003, 64:14-19. 10.4088/JCP.v64n0105, 12590618.
22. Mann JJ, Waternaux C, Haas GL, Malone KM. Toward a clinical model of suicidal behavior in psychiatric patients. Am J Psychiatry 1999, 156:181-189.
23. Nock MK, Hwang I, Sampson NA, Kessler RC. Mental disorders, comorbidity and suicidal behavior: results from the National Comorbidity Survey Replication. Molecular Psychiatry 2010, 15:868-876. 10.1038/mp.2009.29, 19337207.
24. Marangell LB, Bauer MS, Dennehy EB, Wisniewski SR, Allen MH, Miklowitz DJ, Oquendo MA, Frank E, Perlis RH, Martinez JM, Fagiolini A, Otto MW, Chessick CA, Zboyan HA, Miyahara S, Sachs G, Thase ME. Prospective predictors of suicide and suicide attempts in 1,556 patients with bipolar disorders followed for up to 2 years. Bipolar Disord 2006, 8:566-575. 10.1111/j.1399-5618.2006.00369.x, 17042830.
25. Marcangelo MJ, Ovsiew F. Psychiatric aspects of epilepsy. Psychiatr Clin North Am 2007, 30:781-802. 10.1016/j.psc.2007.07.005, 17938045.
26. Meador KJ. Suicide in patients with epilepsy. Epilepsy Curr 2008, 8:40-42. 10.1111/j.1535-7511.2008.00231.x, 2265807, 18330466.
27. Kondziella D, Asztely F. Don't be afraid to treat depression in patients with epilepsy!. Acta Neurol Scand 2009, 119:75-80. 10.1111/j.1600-0404.2008.01088.x, 18759799.
28. Pompili M, Rihmer Z, Innamorati M, Lester D, Girardi P, Tatarelli R. Assessment and treatment of suicide risk in bipolar disorders. Exp Rev Neurother 2009, 9:109-136.
29. Fountoulakis KN, Gonda X, Siamouli M, Rihmer Z. Psychotherapeutic intervention and suicide risk reduction in bipolar disorder: a review of the evidence. J Affect Disord 2009, 113:21-29. 10.1016/j.jad.2008.06.014, 18676024.
30. Willmore LJ, Shu V, Wallin B. Efficacy and safety of add-on divalproex sodium in the treatment of complex partial seizures. The M88-194 Study Group. Neurology 1996, 46:49-53.
31. Pope HG, McElroy SL, Keck PE, Hudson JI. Valproate in the treatment of acute mania. A placebo-controlled study. Arch Gen Psychiatry 1991, 48:62-68.
32. Bowden CL, Brugger AM, Swann AC, Calabrese JR, Janicak PG, Petty F, Dilsaver SC, Davis JM, Rush AJ, Small JG, et al. Efficacy of divalproex vs lithium and placebo in the treatment of mania. The Depakote Mania Study Group. J Am Med Assoc 1994, 271:918-924.
33. Bowden CL, Calabrese JR, McElroy SL, Gyulai L, Wassef A, Petty F, Pope HG, Chou JC, Keck PE, Rhodes LJ, Swann AC, Hirschfeld RM, Wozniak PJ. A randomized, placebo-controlled 12-month trial of divalproex and lithium in treatment of outpatients with bipolar I disorder. Divalproex Maintenance Study Group. Arch Gen Psychiatry 2000, 57:481-489. 10.1001/archpsyc.57.5.481, 10807488.
34. Sachs GS, Althshuler L, Ketter T, Suppes T, Rasgon N, Frye M, Collins M. Divalproex versus placebo in the treatment of bipolar depression. American College of Neuropsychopharmacology 2001, Waikoloa, Hawaii, 40.
35. Hirschfeld R, Bowden C, Vigna N, Wozniak P, Collins M. A randomized, placebo-controlled, multicenter study of divalproex sodium extended-release in the acute treatment of mania. J Clin Psychiatry 2010, 71:426-432. 10.4088/JCP.08m04960yel, 20361904.
36. Tariot PN, Schneider LS, Mintzer JE, Cutler AJ, Cunningham MR, Thomas JW, Sommerville KW. Safety and tolerability of divalproex sodium in the treatment of signs and symptoms of mania in elderly patients with dementia: Results of a Double-Blind, Placebo-Controlled Trial. Curr Ther Res 2001, 62:51-67.
37. Bowden CL, Swann AC, Calabrese JR, Rubenfaer LM, Wozniak PJ, Collins MA, Abi-Saab W, Saltarelli M. A randomized, placebo-controlled, multicenter study of divalproex sodium extended release in the treatment of acute mania. J Clin Psychiatry 2006, 67:1501-1510. 10.4088/JCP.v67n1003, 17107240.
38. Hollander E, Tracy KA, Swann AC, Coccaro EF, McElroy SL, Wozniak P, Sommerville KW, Nemeroff CB. Divalproex in the treatment of impulsive aggression: efficacy in cluster B personality disorders. Neuropsychopharmacology 2003, 28:1186-1197. 10.1038/sj.npp.1300021, 12700713.
39. Mathew NT, Saper JR, Silberstein SD, Rankin L, Markley HG, Solomon S, Rapoport AM, Silber CJ, Deaton RL. Migraine prophylaxis with divalproex. Arch Neurol 1995, 52:281-286.
40. Klapper J. Divalproex sodium in migraine prophylaxis: a dose-controlled study. Cephalalgia 1997, 17:103-108. 10.1046/j.1468-2982.1997.1702103.x, 9137847.
41. Freitag FG, Collins SD, Carlson HA, Goldstein J, Saper J, Silberstein S, Mathew N, Winner PK, Deaton R, Sommerville K. A randomized trial of divalproex sodium extended-release tablets in migraine prophylaxis. Neurology 2002, 58:1652-1659.
42. Beydoun A, Sackellares JC, Shu V. Safety and efficacy of divalproex sodium monotherapy in partial epilepsy: a double-blind, concentration-response design clinical trial. Depakote Monotherapy for Partial Seizures Study Group. Neurology 1997, 48:182-188.